Citadel Advisors
ALZN icon

Citadel Advisors’s Alzamend Neuro ALZN Stock Holding History

Citadel Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$7.39K – 14273
2023
Q1 		$7.39K Sell
13
-15
-54% -$11.3K ﹤0.01% 13729
2022
Q4 		$21.2K Buy
28
+7
+33% +$10.1K ﹤0.01% 13098
2022
Q3 		$34K Sell
21
-13
-38% -$17.9K ﹤0.01% 11838
2022
Q2 		$40K Sell
34
-5
-13% -$6.48K ﹤0.01% 12060
2022
Q1 		$64K Sell
39
-80
-67% -$150K ﹤0.01% 12633
2021
Q4 		$306K Buy
119
+97
+441% +$300K ﹤0.01% 10873
2021
Q3 		$90K Buy
+22
New +$121K ﹤0.01% 12973

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
CSB
City State Bank Norwalk, Iowa $436M AUM 32.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's ALZN Position: Q1 2025 in Review

Citadel Advisors sold out of Alzamend Neuro (ALZN) in Q1 2025, closing a stake of 3,404 shares — an estimated $35.5K sold.

Citadel Advisors first reported a position in ALZN in Q3 2021 and held it in 3 quarters. The position peaked at $139K in Q3 2021. 8 funds tracked by Wall St. Rank hold ALZN as of Q1 2025.

  • Citadel Advisors reported no remaining Alzamend Neuro position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 3,404 Alzamend Neuro shares in Q1 2025, an estimated $35.5K.
  • Citadel Advisors first reported a position in Alzamend Neuro in Q3 2021 and held it in 3 quarters.
  • Citadel Advisors's Alzamend Neuro position peaked at $139K in Q3 2021.
  • 8 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.